Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.42 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in renal collecting duct intercalated cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 70 | 0.85 |
| pathways Reactome | 37 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 0480
Sealed predictions
- NUP160 in oligodendrocytes, braak-0.24 (p 0.539) → -0.52 (p 0.150)receipt 0487
- NUP160 in dopamine neurons, braak+0.30 (p 0.436) → +0.05 (p 0.893)receipt 0488
Swarm cases
receipt 0488: NUP160 in dopamine neurons, braak
- power
- full sample +0.18 (p 0.487, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.25 (p 0.315, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.25 (p 0.315, n 18). could be the mix.
- skeptic
- leave-one-out range +0.07 to +0.28, sign flips 0; without severely affected donors +0.18 (p 0.487, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NUP160 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0487: NUP160 in oligodendrocytes, braak
- power
- full sample -0.36 (p 0.137, n 18), 95% CI -0.71 to +0.12. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.34 (p 0.170, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.37 (p 0.135, n 18). could be the mix.
- skeptic
- leave-one-out range -0.56 to -0.28, sign flips 0; without severely affected donors -0.36 (p 0.137, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NUP160 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts